{
    "code": 0,
    "data": [
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results_31.12.2025",
            "news_body": "Unaudited standalone and consolidated financial results for the quarter ended 31.12.2025.",
            "news_id": "c81c362b-fdad-43ca-b034-e924b1228680",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=02b038d5-d692-43e3-926a-a3c2ae50863a.pdf",
            "news_date": "2026-02-11 19:03:12",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.09.2025",
            "news_body": "Unaudited standalone and Consolidated financial results for the quarter ended 30.09.2025.",
            "news_id": "03fce482-e86e-46fd-8e98-f439c72b9a45",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=42dde0cc-3aff-405f-9f73-ecd86fafc6a5.pdf",
            "news_date": "2025-11-12 18:56:34",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial For The Quarter Ended 30.06.2025.",
            "news_body": "Unaudited financial results ( Standalone and consolidated )  for the quarter ended 30.06.2025.",
            "news_id": "e62b311d-ea2f-4a8f-b4a2-09dcee381e3e",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5da811ea-f250-4bf0-af0d-ec193eca38b5.pdf",
            "news_date": "2025-08-11 18:09:49",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Standalone And Consolidated Financial Results For The Quarter Ended 31.12.2024.",
            "news_body": "The Board of Directors at their meeting held on 13.02.2025 has taken on record and approved Un audited financial results of the Company for the quarter ended 31.12.2024.\r\n\r\nCopy of the financial results together with limited review report issued by statutory auditors is enclosed.",
            "news_id": "882a9bb3-9f77-410b-8d3d-b41d62841645",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=60694750-63e0-4871-8d03-a6ff0fe2011a.pdf",
            "news_date": "2025-02-13 18:14:22",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30.09.2024.",
            "news_body": "The Board of Directors at their meeting held on 13.02.2025 has inter alia taken on record and approved the stand alone and consolidated financial results of the Company.\r\n\r\nCopy of financial results  Limited review report issued by statutory auditors together with declaration of unmodified opinion is enclosed . \r\n\r\nPlease take the same on record.",
            "news_id": "6ed05334-7b0a-45a9-af79-6e2ec7b53d36",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6b9c1503-551d-46b8-aea6-dbc9b11688d0.pdf",
            "news_date": "2025-02-13 17:44:34",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended 30.09.2024.",
            "news_body": "Board of Directors at their meeting held on 14.11.2024 has inter alia taken on record and approved the Un-audited financial results of the Company for the quarter and half year ended 30.09.2024.",
            "news_id": "a8959049-992a-4706-ade1-1c0539890571",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7826be06-be73-4b4d-9eef-504e2e17522a.pdf",
            "news_date": "2024-11-14 17:28:05",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.06.2024.",
            "news_body": "Taken on record and Approved the Unaudited financial results of the  Company for the quarter ended 30.06.2024.",
            "news_id": "7a0ce33e-8bdf-45be-b8dd-857cc3d73aac",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=dc83ca16-90dd-4131-8584-b60159279e4b.pdf",
            "news_date": "2024-08-12 18:04:10",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results_31.03.2024",
            "news_body": "Audited stand alone & Consolidated financial results for the quarter and financial year  ended 31.03.2024 to gather with declaration of unmodified opinion and audit reports issued by statutory auditors.",
            "news_id": "ba669cb8-5926-4b12-97c8-8164341bf681",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=47ef817f-7f7a-4f05-b43e-9c591c375841.pdf",
            "news_date": "2024-05-28 18:04:19",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 31.12.2023.",
            "news_body": "Unaudited standalone and consolidated Financial results for the quarter and 9 months ended 31.12.2023.",
            "news_id": "06744409-c866-4e7b-a323-bb67874da93c",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77b3a08c-6431-41c2-99f7-6f81a4ac327c.pdf",
            "news_date": "2024-02-12 18:00:01",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2023.",
            "news_body": "The Board of Directors of the Company has inter alia taken on record and approved the unaudited financial result of the Company for the quarter and half year ended 30.09.2023",
            "news_id": "11666253-a9a8-447a-b409-c521664d7804",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00eaa93b-8e87-4ee1-adb0-56055f4fcfe6.pdf",
            "news_date": "2023-11-08 17:58:00",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results - Stand Alone And Consolidated For The Quarter And Year Ended 31.03.2023",
            "news_body": "The Board of Directors of the Company has met today and inter alia transacted the following business.<BR> <BR> 1.Approved the Audited Standalone and Consolidated Financial Results of the Company for the quarter and financial year ended 31.03.2023. A copy of the Audited financial statements (Standalone and Consolidated) along with auditors reports with unmodified opinion are enclosed with this letter for submission to the exchanges. <BR> <BR> 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each i.e 10%, subject to the approval of members at the ensuing Annual General Meeting of the Company. <BR> <BR> 3.Appointed Mr.M.R Krishna Murthy (Membership No. 7568) as Cost Auditor , Mr.Parameshwar Bhat (Membership No.8860) as Secretarial Auditors and Messrs. Murugesh & Co ( Membership No.002233S) as internal auditors of the Company for the financial year 2023-2024.<BR> <BR> The meeting commenced at 4.45 P.M and concluded at 6.20 P.M on 29.05.2023.<BR>",
            "news_id": "4df15b80-d780-4c75-a4c9-1e40d91b90db",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=27ca1282-0c8b-4958-b8a4-f1bc67065e2a.pdf",
            "news_date": "2023-05-29 19:28:24",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Nine Months Ended 31.12.2022.",
            "news_body": "Board of Directors of the Company has met today and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and nine months ended 31.12.2022. A copy of the standalone and consolidated financial results together with the limited review reports issued by the statutory auditors of the Company with un modified opinion, is enclosed.<BR> <BR> The Board meeting commenced at 4.30 p.m and concluded at 6.20 p.m on 06.02.2023.<BR> <BR> <BR> <BR>",
            "news_id": "2c64f97c-fb27-48e9-87d5-01a8aafdf8e3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=79efc482-da67-45a6-84d6-c62654bd7c52.pdf",
            "news_date": "2023-02-06 18:42:57",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Disclosure Of Related Party Transactions",
            "news_body": "We are submitting to the exchanges statement of the related party transactions of the Com[pany for the half year ended 30.09.2022.",
            "news_id": "74a3b7bb-4af6-4168-a397-0bb4fa4df1fb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cfda30a-5b0b-4f03-85b0-b58f27e42d8a.pdf",
            "news_date": "2022-11-28 13:47:54",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter And Half Year Ended 30.09.2022.",
            "news_body": "Board of Directors of the Company has met today and inter alia transacted the following  business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2022. A copy of the standalone and consolidated financial results together with the balance sheets, cash flow statements and limited review reports issued by the statutory auditors of the Company with un modified opinion is enclosed .<BR> <BR> 2.Convened Extra Ordinary meeting of the shareholders of the Company on 14th December 2022 to take their approval for filing application with NCLT for the merger of Golden Drugs Pvt Ltd, a wholly owned subsidiary of the Company.<BR> <BR> 3.Approved the allotment of 1,17,500 equity shares to the employees of the Company who has exercised the stock options vested on them, under Bal Pharma Ltd employee stock option plan 2014. <BR> <BR> The Board meeting commenced at 5.30 p.m and concluded at 6.20 p.m on 14.11.2022.<BR>",
            "news_id": "f334876b-b3a3-4f72-8352-93b57d9395ba",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3307a810-c82b-464f-9b69-8ecc771b3ea8.pdf",
            "news_date": "2022-11-14 19:07:25",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Audio Visual recording of the webinar can we assessed through the following weblink https://www.balpharma.com/ip",
            "news_id": "cc86aceb-e484-4fe4-963c-8e9812ee4027",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8c57bc7f-1788-4b09-bfe5-c2095e5c7f63.pdf",
            "news_date": "2022-09-23 12:24:37",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "We are submitting the revised Investor presentation on the performance of the Company for the quarter ended 30.06.2022.",
            "news_id": "76a8f838-f5f7-4a1f-a0c2-fea11b110d2d",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4561806c-b55c-4560-aaec-2d919e9d735e.pdf",
            "news_date": "2022-09-07 16:51:35",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Investor Presentation",
            "cat": "Investor Presentation",
            "caption": "Announcement under Regulation 30 (LODR)-Investor Presentation",
            "news_body": "Investor Presentation for Q1 FY 23",
            "news_id": "04fe1663-f557-4eff-8c22-f7f399ca22ee",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9ffac35-8f79-45a2-b88b-9a88e106e075.pdf",
            "news_date": "2022-09-06 17:07:27",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Un-Audited Financial Results For The Quarter Ended 30.06.2022.",
            "news_body": "Board of Directors of the Company at their meeting held on 11.08.2022 has inter alia taken on record and  approved the Un-audited financial results of the Company for the quarter ended 30.06.2022. <BR> <BR> Financial results along with the limited review reports issued by the statutory auditors of the Company are enclosed.",
            "news_id": "0f58910f-4b75-4fb3-b25a-2f530ef466a6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d03990f7-f009-4d3f-a463-f7079c56284d.pdf",
            "news_date": "2022-08-11 16:12:41",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "Board of Directors of the Company has inter alia taken on record and approved the un-audited financial results ( stand alone & consolidated ) of the Company for the quarter ended 30.06.2022.",
            "news_id": "bac22536-4e8f-4314-896e-acf3beac0ba3",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cb293dc8-2aa9-43bb-8842-5998a1be3e99.pdf",
            "news_date": "2022-08-11 16:06:59",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Declaration Of Unmodified Opinion_ Audited Financial Results",
            "news_body": "Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company viz. NSVM & Associates, Chartered Accountants, having membership # 010072S have issued audit report with Unmodified opinion on audited Standalone and Consolidated Financial Statements of the Company, for the quarter and year ended March 31, 2022.<BR> <BR> The declaration of unmodified opinion was confirmed by the auditors in their audit report and the same was submitted to the exchanges vide our submission dated 30.05.2022.<BR> <BR>",
            "news_id": "77ebf227-bb92-402c-a651-0ea438f79dc7",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fe9849f2-0d7b-4325-bad7-94e45e25c951.pdf",
            "news_date": "2022-06-08 15:27:00",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For F.Y 2021-22.",
            "news_body": "The Board of Directors of the Company has met today and inter alia transacted the following business.<BR> <BR> 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2022. A copy of the Audited financials (Standalone and Consolidated) along with auditors report's are enclosed with this letter for submission to the exchanges. <BR> <BR> 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. <BR> <BR>",
            "news_id": "6b5de63a-08e4-4f0a-8672-f6d6ccc1141a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7b2767d4-b010-466c-bf23-3cfde80350a9.pdf",
            "news_date": "2022-05-30 18:20:44",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The Board Meeting",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> Taken on record and approved the Unaudited financial results of the Company for the quarter ended 31.12.2021. Copy of the standalone and consolidated financial results along with the limited review reports with unmodified opinions issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 and concluded at 18.00 hours on 10.02.2022.<BR>",
            "news_id": "51c2d275-8ac4-4981-b8ff-215eb67b1eeb",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9115eaf7-7692-4132-99a3-4298b6609a48.pdf",
            "news_date": "2022-02-10 18:38:48",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Standalone & Consolidated Financial Results_31.12.2021",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> Taken on record and approved the Unaudited financial results of the Company for the quarter ended 31.12.2021. Copy of the standalone and consolidated financial results along with the limited review reports with unmodified opinions issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 and concluded at 18.00 hours on 10.02.2022.<BR>",
            "news_id": "3969ffc8-d8ed-4d4b-affb-1d2a5bcf124b",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f2f096bc-a9d8-4c97-bafb-933488b73e26.pdf",
            "news_date": "2022-02-10 18:15:57",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Financial Results For Quarter And Half Year Ended 30.09.2021",
            "news_body": "We are resubmitting the higher resolution , clear and legible financial results of the Company for the quarter and half year ended 30.09.2021.",
            "news_id": "0eb4fc22-b885-40fd-b41c-edec55ca130a",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d00fbc4b-bf39-496f-9083-095d30f5da82.pdf",
            "news_date": "2021-12-09 15:32:12",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Standalone & Consolidated Financial Results_30.09.2021",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2021. Copy of the standalone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 p.m and concluded at 18.00 on 11.11.2021.<BR> <BR>",
            "news_id": "e32dd6a0-b7c2-4598-ad93-49e246908fb2",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4c71194f-4bee-471b-ae05-9b04a893554e.pdf",
            "news_date": "2021-11-11 18:06:20",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Board Meeting Outcome for Outcome Of The  Board Meeting",
            "news_body": "The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter and half year ended 30.09.2021. Copy of the standalone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> The meeting commenced at 16.30 p.m and concluded at 18.00 on 11.11.2021.<BR> <BR> <BR>",
            "news_id": "23e6209e-bf4d-430a-ae5d-3cc59c2e8256",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cd05f26a-0059-4eb3-8102-fd260cdc6b24.pdf",
            "news_date": "2021-11-11 17:58:32",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Unaudited Financial Results For The Quarter Ended 30.06.2021.",
            "news_body": "Out come of the Board Meeting.<BR> <BR> The Board of Directors of the Company has met to day and inter alia transacted the following business.<BR> <BR> 1.Taken on record and approved the Unaudited financial results of the Company for the quarter ended 30.06.2021. Copy of the stand alone and consolidated financial results along with the limited review reports issued by the statutory auditors of the Company is enclosed, for submission to the exchanges.<BR> <BR> 2.Approved the grant of 4,16,500 stock options to the employees of the Company under Bal Pharma Ltd - Employee Stock Option Plan -2014.<BR> <BR> The meeting commenced at 16.30 p.m and concluded at 17.30 on 10.08.2021.<BR>",
            "news_id": "6c5e3543-c9b6-4024-a00f-be211586b7b6",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=415cf4a0-4965-4cd4-bf52-35cb3327a26e.pdf",
            "news_date": "2021-08-10 17:43:14",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Declaration Of Unmodified Opinion.",
            "news_body": "Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby declare and confirm that the Statutory Auditors of the Company viz. NSVM & Associates, Chartered Accountants, having membership # 010072S have issued audit report with Unmodified opinion on audited Standalone and Consolidated Financial Statements of the Company, for the year ended March 31, 2021.<BR> <BR>",
            "news_id": "99fbb52e-8196-4359-bb86-a5f5ba7990cc",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d458540c-29af-4f39-a140-532d219f28e1.pdf",
            "news_date": "2021-07-06 12:21:32",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        },
        {
            "sym": "BALPHARMA",
            "disp": "Bal Pharma",
            "bse_code": 524824,
            "isin": "INE083D01012",
            "descriptor": "Financial Results",
            "cat": "Financial Results",
            "caption": "Audited Financial Results For Quarter And Financial Year Ended 31.03.2021.",
            "news_body": "The Board of Directors of the Company has met today and inter alia transacted the following business.<BR> 1.Approved the Audited Financial Results of the Company for the quarter and financial year ended 31.03.2021. A copy of the Audited financials (Standalone and Consolidated) along with audit report's are enclosed with this letter for submission to the exchanges. <BR> 2.Recommended dividend of Re.1/- per equity share of Rs.10/- each, payable subject to the approval of members at the ensuing Annual General Meeting of the Company. <BR> 4. Decided to convene the 34th Annual General Meeting of the Company on Friday 24th September, 2021, by audio visual means.<BR> 5.Decided to close the Register of Members and Share Transfer books of the Company from 18th September 2021 to 24th September 2021 (Both days inclusive).<BR> 6.The Board considered and authorised Mr.Shailesh Siroya, Managing Director  to undertake restructuring process of the group Companies, subject to various legal and taxation aspects.   <BR> <BR>",
            "news_id": "50b4c7d8-ee3d-436f-b471-0a9411a105c4",
            "file_url": "https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d7df3c76-832b-4931-a19f-bbef0a961316.pdf",
            "news_date": "2021-06-29 17:53:42",
            "seo": "bal-pharma-ltd",
            "ltp": 71.74,
            "ch": 1.6499999999999915,
            "pch": 2.35411613639605,
            "inst": "EQUITY",
            "ts": 0.01,
            "ls": 1,
            "mtp": 1,
            "sid": 13441,
            "exch": "NSE",
            "seg": "E"
        }
    ],
    "remarks": ""
}